Journal
Journal of Clinical Oncology
Publication Date
6-1-2023
Volume
41
Issue
16
First Page
2893
Last Page
2903
Document Type
Open Access Publication
DOI
10.1200/JCO.22.02823
Rights and Permissions
Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/
Recommended Citation
Paz-Ares, Luis; Govindan, Ramaswamy; and et al., "Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: An open-label, Phase I study." Journal of Clinical Oncology. 41, 16. 2893 - 2903. (2023).
https://digitalcommons.wustl.edu/oa_4/2190
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
